Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia

  • Medina-Gil, Daniel|||0000-0001-9421-949X
  • Palomo Sanchís, Laura|||0000-0003-3176-6271
  • Navarro Garcés, Víctor|||0000-0001-6925-4605
  • Lázaro, Gonzalo|||0000-0002-7548-114X
  • Martín-Mur, Beatriz|||0000-0002-6006-3295
  • Hernández Buñuel, Cristina
  • Castells, Oriol
  • Sánchez, Belén
  • Muñoz-Torres, Pau Marc|||0000-0002-0168-3224
  • Pagès Geli, Carlota|||0000-0001-9200-3943
  • Pujadas, Gemma|||0000-0002-3871-5883
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Cabirta, Alba|||0000-0001-7198-8894
  • Ferrá, Christelle|||0000-0003-4571-5125
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Terol, Maria Jose|||0000-0002-9467-932X
  • Andreu, Rafael|||0000-0002-9220-3352
  • Martí, Mercè|||0000-0002-1846-0043
  • Abrisqueta, Pau|||0000-0001-9625-7422
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
  • Crespo, Marta|||0000-0002-7732-7808
Continuous treatment with ibrutinib not only exerts tumor control but also enhances T-cell function in patients with chronic lymphocytic leukemia (CLL). We conducted longitudinal multi-omics analyses in samples from CLL patients receiving ibrutinib upfront to identify potential adaptive mechanisms to Bruton tyrosine kinase (BTK) inhibition during the first 12 months of continuous therapy. We found that ibrutinib induced a decrease in the expression of exhaustion markers and the proportion of regulatory T cells and T-follicular helper cells normalized to levels observed in healthy donors. Functionally, the expression of genes related to activation, proliferation, differentiation, and metabolism were downregulated in T cells; after in vitro stimulation, proliferation capacity was only slightly modified by ibrutinib treatment, while cytokine production was increased. In CLL cells, we observed a downregulation of immunosuppression, adhesion, and migration proteins. Adaptation at molecular level, characterized by an increase in cancer cell fraction of CLL cells with mutated driver genes, was observed in around half of the patients and was associated with retained migrative capacity towards CXCL12/CXCR4 axis. Interestingly, BTK C481S mutations were detected as early as after 6 months of treatment, particularly enriched in subsets of malignant cells retaining migrative capacity. These CLL cells with potential migrative capacity under ibrutinib also exhibited a distinct transcriptomic profile including upregulation of mTOR-AKT and MYC pathways. We identified the high expression of TMBIM6 as a potential novel independent poor prognostic factor. Of note, BIA, a TMBIM6 antagonist, induced CLL cell apoptosis and synergized with ibrutinib. In summary, our comprehensive multi-omics analysis of CLL patients undergoing ibrutinib therapy has unveiled early immunomodulatory effects on T cells and adaptative mechanisms in CLL cells. These findings can contribute to the identification of resistance mechanisms and the discovery of novel therapeutic targets.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression

  • Abrisqueta, Pau|||0000-0001-9625-7422
  • Medina, Daniel
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • Lu, Junyan
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Carabia, Júlia
  • Boix, Joan
  • Tazón-Vega, Barbara
  • Iacoboni, Gloria|||0000-0003-0805-9288
  • Bobillo, Sabela|||0000-0001-7381-680X
  • Marín-Niebla, Ana|||0000-0002-7592-6815
  • González, Marcos
  • Zenz, Thorsten|||0000-0001-7890-9845
  • Crespo Maull, Marta|||0000-0002-7732-7808
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
Several gene expression profiles with a strong correlation with patient outcomes have been previously described in chronic lymphocytic leukemia (CLL), although their applicability as biomarkers in clinical practice has been particularly limited. Here we describe the training and validation of a gene expression signature for predicting early progression in patients with CLL based on the analysis of 200 genes related to microenvironment signaling on the NanoString platform. In the training cohort (n = 154), the CLL15 assay containing a 15-gene signature was associated with the time to first treatment (TtFT) (hazard ratio [HR], 2.83; 95% CI, 2.17-3.68; P <.001). The prognostic value of the CLL15 score (HR, 1.71; 95% CI, 1.15-2.52; P =.007) was further confirmed in an external independent validation cohort (n = 112). Notably, the CLL15 score improved the prognostic capacity over IGHV mutational status and the International Prognostic Score for asymptomatic early-stage (IPS-E) CLL. In multivariate analysis, the CLL15 score (HR, 1.83; 95% CI, 1.32-2.56; P <.001) and the IPS-E CLL (HR, 2.23; 95% CI, 1.59-3.12; P <.001) were independently associated with TtFT. The newly developed and validated CLL15 assay successfully translated previous gene signatures such as the microenvironment signaling into a new gene expression-based assay with prognostic implications in CLL.